Resistance of ERBB2 KD mutants to tesevatinib

Stable Identifier
R-HSA-9665245
Type
Pathway
Species
Homo sapiens
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser

This pathway describes resistance of ERBB2 KD mutants to tyrosine kinase inhibitor tesevatinib (Trowe et al. 2018).

Literature References
PubMed ID Title Journal Year
18413839 EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation

Trowe, T, Boukouvala, S, Calkins, K, Cutler, RE, Fong, R, Funke, R, Gendreau, SB, Kim, YD, Miller, N, Woolfrey, JR, Vysotskaia, V, Yang, JP, Gerritsen, ME, Matthews, DJ, Lamb, P, Heuer, TS

Clin. Cancer Res. 2008
Participants
Participant Of
Disease
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created
Cite Us!